Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs.
Estimates
HCV
IDU
PWID
injecting drug use
viraemic
Journal
Addiction (Abingdon, England)
ISSN: 1360-0443
Titre abrégé: Addiction
Pays: England
ID NLM: 9304118
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
08
01
2018
revised:
29
03
2018
accepted:
12
07
2018
pubmed:
24
7
2018
medline:
7
3
2020
entrez:
24
7
2018
Statut:
ppublish
Résumé
People who have recently injected drugs are a priority population in efforts to achieve hepatitis C virus (HCV) elimination. This study estimated the prevalence and number of people with recent injecting drug use living with HCV, and the proportion of people with recent injecting drug use among all people living with HCV infection at global, regional and country-levels. Data from a global systematic review of injecting drug use and HCV antibody prevalence among people with recent (previous year) injecting drug use were used to estimate the prevalence and number of people with recent injecting drug use living with HCV. These data were combined with a systematic review of global HCV prevalence to estimate the proportion of people with recent injecting drug use among all people living with HCV. There are an estimated 6.1 million [95% uncertainty interval (UI) = 3.4-9.2] people with recent injecting drug use aged 15-64 years living with HCV globally (39.2% viraemic prevalence; UI = 31.6-47.0), with the greatest numbers in East and Southeast Asia (1.5 million, UI = 1.0-2.1), eastern Europe (1.5 million, UI = 0.7-2.4) and North America (1.0 million, UI = 0.4-1.7). People with recent injecting drug use comprise an estimated 8.5% (UI = 4.6-13.1) of all HCV infections globally, with the greatest proportions in North America (30.5%, UI = 11.7-56.7), Latin America (22.0%, UI = 15.3-30.4) and eastern Europe (17.9%, UI = 8.2-30.9). Although, globally, 39.2% of people with recent injecting drug use are living with hepatitis C virus (HCV) and 8.5% of all HCV infections occur globally among people with recent injecting drug use, there is wide variation among countries and regions.
Sections du résumé
BACKGROUND AND AIMS
People who have recently injected drugs are a priority population in efforts to achieve hepatitis C virus (HCV) elimination. This study estimated the prevalence and number of people with recent injecting drug use living with HCV, and the proportion of people with recent injecting drug use among all people living with HCV infection at global, regional and country-levels.
METHODS
Data from a global systematic review of injecting drug use and HCV antibody prevalence among people with recent (previous year) injecting drug use were used to estimate the prevalence and number of people with recent injecting drug use living with HCV. These data were combined with a systematic review of global HCV prevalence to estimate the proportion of people with recent injecting drug use among all people living with HCV.
RESULTS
There are an estimated 6.1 million [95% uncertainty interval (UI) = 3.4-9.2] people with recent injecting drug use aged 15-64 years living with HCV globally (39.2% viraemic prevalence; UI = 31.6-47.0), with the greatest numbers in East and Southeast Asia (1.5 million, UI = 1.0-2.1), eastern Europe (1.5 million, UI = 0.7-2.4) and North America (1.0 million, UI = 0.4-1.7). People with recent injecting drug use comprise an estimated 8.5% (UI = 4.6-13.1) of all HCV infections globally, with the greatest proportions in North America (30.5%, UI = 11.7-56.7), Latin America (22.0%, UI = 15.3-30.4) and eastern Europe (17.9%, UI = 8.2-30.9).
CONCLUSIONS
Although, globally, 39.2% of people with recent injecting drug use are living with hepatitis C virus (HCV) and 8.5% of all HCV infections occur globally among people with recent injecting drug use, there is wide variation among countries and regions.
Identifiants
pubmed: 30035835
doi: 10.1111/add.14393
pmc: PMC6657799
mid: NIHMS1037301
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
150-166Subventions
Organisme : Department of Health
ID : RP-PG-0616-20008
Pays : United Kingdom
Organisme : UNAIDS
Pays : International
Organisme : Open Society Foundation
Pays : International
Organisme : John C Martin Foundation
Pays : International
Organisme : National Drug and Alcohol Research Centre
Pays : International
Organisme : NIDA NIH HHS
ID : R01 DA044170
Pays : United States
Organisme : World Health Organization
Pays : International
Organisme : Medical Research Council
ID : MR/K006525/1
Pays : United Kingdom
Organisme : The Global Fund
Pays : International
Organisme : NIDA NIH HHS
ID : R01 DA037773
Pays : United States
Organisme : National Health and Medical Research Council
Pays : International
Organisme : Department of Health
ID : RP-DG-0610-10055
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2018 Society for the Study of Addiction.
Références
Clin Infect Dis. 2017 Apr 1;64(7):860-869
pubmed: 28362947
Lancet Gastroenterol Hepatol. 2017 Mar;2(3):161-176
pubmed: 28404132
Liver Int. 2014 Sep;34(8):1198-206
pubmed: 24164865
J Int AIDS Soc. 2017 Jul 28;20(1):22146
pubmed: 28782335
Lancet. 2008 Nov 15;372(9651):1733-45
pubmed: 18817968
Clin Infect Dis. 2013 Aug;57 Suppl 2:S32-8
pubmed: 23884063
Addiction. 2018 Mar;113(3):545-563
pubmed: 28891267
Int J Drug Policy. 2017 Sep;47:34-46
pubmed: 28797498
J Viral Hepat. 2009 May;16(5):352-8
pubmed: 19226330
BMC Infect Dis. 2016 Sep 05;16:471
pubmed: 27595855
Am J Epidemiol. 2008 Nov 15;168(10):1099-109
pubmed: 18849303
J Community Health. 2008 Jun;33(3):126-33
pubmed: 18165889
Lancet Glob Health. 2017 Dec;5(12):e1192-e1207
pubmed: 29074409
J Viral Hepat. 2014 Mar;21(3):198-207
pubmed: 24438681
Clin Infect Dis. 2005 Apr 15;40 Suppl 5:S304-12
pubmed: 15768339
Lancet. 2011 Aug 13;378(9791):571-83
pubmed: 21802134
PLoS One. 2014 Jul 28;9(7):e103345
pubmed: 25068274
Hepatology. 2014 Jan;59(1):109-20
pubmed: 23908124